Bexsero MenB vaccine for UKHSA comes from GlaxoSmithKline
- UK Health Security Agency
- London
- Direct award
- 1 October 2026 to 30 September 2029
The UK Health Security Agency is buying Bexsero, a meningococcal group B (MenB) vaccine, from GlaxoSmithKline.
The vaccine is used in the national programme of childhood immunisation. A second, targeted programme uses it to protect adults at risk of gonorrhoea. Supply follows advice from the JCVI.
The agency announced in advance that it intended to negotiate with GlaxoSmithKline, then awarded the contract directly in May 2026. The contract can run to September 2030 with extensions. The value was withheld from publication to protect the supplier's commercial interests.
Contract ends September 2029
- What
- Vaccines and immunisation products
- Supplier
- GlaxoSmithKline
- Value
- Not published
- How it was bought
- Direct award
- Dates and next
- Oct 2026 to Sep 2029
- Being re-tendered now